IP Library Granted Patent US 7,410,656
Granted Patent B2
US 7,410,656 · App. 10/896,811 · Granted Aug 12, 2008

Anti-cancer compounds

Assignee: Peplin Research Pty. Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,410,656
App. No.
10/896,811
Granted
Aug 12, 2008
Kind
B2
Abstract

This invention relates to a compound or group of compounds present in an active principle derived from plants of species Euphorbia peplus, Euphorbia hirta and Euphorbia drummondii , and to pharmaceutical compositions comprising these compounds. Extracts from these plants have been found to show selective cytotoxicity against several different cancer cell lines. The compounds are useful in effective treatment of cancers, particularly malignant melanomas and squamous cell carcinomas (SCCs). In a preferred embodiment of the invention, the compound is selected from the group consisting of jatrophanes, pepluanes, paralianes and ingenanes, and pharmaceutically-acceptable salts or esters thereof, and more particularly jatrophanes of Conformation II.

Claims (6)

1. A method for inhibiting proliferative activity of neoplastic cells in a subject, said method comprising administering to a subject in need thereof a therapeutically effective amount of an isolated compound, said compound being an angeloyl-substituted ingenane.

2. The method of claim 1 , wherein the compound is selected from the group consisting of an angeloyl-substituted ingenane with an acylated substitution on or at the C-20 position.

3. The method of claim 1 , wherein the compound is 20-O-acetyl-ingenol-3-angelate.

4. The method of claim 1 wherein the neoplastic cells are present in a subject with cancer or a tumor.

5. The method of claim 4 wherein the cancer or tumor is selected from the group consisting of skin cancer, malignant melanoma, merkel cell carcinoma, squamous cell carcinoma, basal cell carcinoma and solar keratosis.

6. The method of claim 4 wherein the cancer or tumor is selected from the group consisting of a solid tumor, lung cancer, colon cancer, prostate cancer, cervical cancer and breast cancer.

Assignments (7)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR PREVIOUSLY RECORDED ON REEL 027560 FRAME 0714. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ASSIGNOR'S INTEREST. Recorded Mar 19, 2012
From: AYLWARD, JAMES HARRISON
To: PEPLIN RESEARCH PTY LTD
Reel/Frame 027887/0382 →
CHANGE OF NAME Recorded Jan 19, 2012
From: PEPLIN BIOTECH LTD.
To: PEPLIN PTY LTD.
Reel/Frame 027561/0121 →
CHANGE OF NAME Recorded Jan 19, 2012
From: PEPLIN PTY. LTD.
To: PEPLIN RESEARCH PTY LTD.
Reel/Frame 027561/0242 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2012
From: AYLWARD, JAMES HARRISON
To: PEPLIN BIOTECH LTD.
Reel/Frame 027560/0714 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2012
From: AKTIESELSKABET AF 30. APRIL 2003
To: LEO LABORATORIES LIMITED
Reel/Frame 027563/0338 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2012
From: PEPLIN RESEARCH PTY LTD AS TRUSTEE FOR THE PEPLIN UNIT TRUST
To: AKTIESELSKABET AF 30. APRIL 2003
Reel/Frame 027563/0527 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2012
From: PEPLIN IRELAND LTD
To: AKTIESELSKABET AF 30. APRIL 2003
Reel/Frame 027563/0311 →
Priority Claims (1)
AU PO 8640 · Aug 19, 1997 · national
Continuity (3)
Continuation 0988817800 · Jun 21, 2001
Continuation 0948619900
Related Publication 20050003031A1 · Jan 6, 2005